<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="74957"><DrugName>cerliponase alfa</DrugName><DrugNamesKey><Name id="43085968">Brineura</Name><Name id="43038056">cerliponase alfa</Name></DrugNamesKey><DrugSynonyms><Name><Value>tripeptidyl peptidase 1 enzyme replacement therapy (LINCL), BioMarin Pharmacutical</Value></Name><Name><Value>cerliponase alfa</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>BMN-190</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Brineura</Value><Types><Type>Trade Name</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20638">University of Medicine and Dentistry of New Jersey</CompanyOriginator><CompaniesPrimary><Company id="25861">BioMarin Pharmaceutical Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="20638">University of Medicine and Dentistry of New Jersey</Company></CompaniesSecondary><CrossReferences><SourceEntity id="74957" type="Drug"><TargetEntity id="780907" type="siDrug">Cerliponase alfa</TargetEntity></SourceEntity><SourceEntity id="20638" type="Company"><TargetEntity id="4296715677" type="organizationId">University of Medicine and Dentistry of New Jersey</TargetEntity></SourceEntity><SourceEntity id="25861" type="Company"><TargetEntity id="4295912660" type="organizationId">Biomarin Pharmaceutical Inc</TargetEntity></SourceEntity><SourceEntity id="2057" type="ciIndication"><TargetEntity id="168491" type="ORPHANET"/></SourceEntity><SourceEntity id="PTGT-06306" type="ciTarget"><TargetEntity id="93104011412003" type="siTarget">Tripeptidyl-peptidase 1</TargetEntity><TargetEntity id="-1644403904" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Jansky-Bielschowsky disease - Argentina - Jun-2017</FirstLaunched><FirstLaunched>Jansky-Bielschowsky disease - US - Jun-2017</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><RegulatoryDesignation id="9">Paediatric Investigation Plan</RegulatoryDesignation><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><RegulatoryDesignation id="13">Rare Pediatric Disease</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="2057">Jansky-Bielschowsky disease</Indication></IndicationsPrimary><ActionsPrimary><Action id="32588">Tripeptidyl peptidase 1 stimulator</Action></ActionsPrimary><ActionsSecondary><Action id="1615">Neuroprotectant</Action></ActionsSecondary><Technologies><Technology id="901">Recombinant enzyme</Technology><Technology id="653">Intracerebroventricular formulation</Technology><Technology id="740">Infusion</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><LastModificationDate>2019-06-13T13:43:48.000Z</LastModificationDate><ChangeDateLast>2019-03-01T00:00:00.000Z</ChangeDateLast><AddedDate>2011-12-10T04:19:28.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="25861" linkType="Company"&gt;BioMarin Pharmaceutical&lt;/ulink&gt;, under license from the &lt;ulink linkID="20638" linkType="Company"&gt;University of Medicine and Dentistry of New Jersey&lt;/ulink&gt;, has developed and launched cerliponase alfa (BMN-190; Brineura), a recombinant human tripeptidyl peptidase-1 (TPP1; CLN2) enzyme replacement therapy. The product is indicated in the US to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2; Jansky-Bielschowsky disease), also known as tripeptidyl peptidase1 (TPP1) deficiency  (a form of Batten disease)  [&lt;ulink linkID="1922391" linkType="Reference"&gt;1922391&lt;/ulink&gt;]. In the EU, cerliponase alfa   is indicated for the treatment of pediatric patients from birth with CLN2 [&lt;ulink linkID="1933418" linkType="Reference"&gt;1933418&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2017, the drug was launched in the US [&lt;ulink linkID="2008438" linkType="Reference"&gt;2008438&lt;/ulink&gt;]. In July 2017, the product was commercially launched in France and Germany [&lt;ulink linkID="1950058" linkType="Reference"&gt;1950058&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;Orphan exclusivity expires in the US and EU in 2024 and 2027, respectively. Biologic exclusivity in the US expires in 2029. In February 2019, Biomarin noted that it owned 13 issued patents, including in the US and outside the US, and 19 pending applications including one US and 18 foreign applications. These patents are to  expire between 2021and 2036 [&lt;ulink linkID="2125627" linkType="Reference"&gt;2125627&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In August 2016, an early access program was initiated in Germany and US [&lt;ulink linkID="1796704" linkType="Reference"&gt;1796704&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In July 2016, the FDA accepted for review a BLA submission for Batten disease. At that time, the FDA granted Priority Review with a PDUFA date of January 27, 2017 [&lt;ulink linkID="1783619" linkType="Reference"&gt;1783619&lt;/ulink&gt;]. In September 2016, additional data was submitted following an FDA request. The PDUFA date was extended to April 27, 2017 [&lt;ulink linkID="1794460" linkType="Reference"&gt;1794460&lt;/ulink&gt;], [&lt;ulink linkID="1903957" linkType="Reference"&gt;1903957&lt;/ulink&gt;].  In April 2017, the FDA approved cerliponase alfa for the treatment of  pediatric patients. At that time, the FDA also issued a Rare Pediatric Disease Priority Review Voucher [&lt;ulink linkID="1922126" linkType="Reference"&gt;1922126&lt;/ulink&gt;], [&lt;ulink linkID="1922125" linkType="Reference"&gt;1922125&lt;/ulink&gt;], [&lt;ulink linkID="1922370" linkType="Reference"&gt;1922370&lt;/ulink&gt;]. In June 2017, the drug was launched in the US [&lt;ulink linkID="1950058" linkType="Reference"&gt;1950058&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2016, the drug was available in the US and Germany through  an early access program [&lt;ulink linkID="1796704" linkType="Reference"&gt;1796704&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2013, the FDA granted Orphan designation for CLN2 [&lt;ulink linkID="1398195" linkType="Reference"&gt;1398195&lt;/ulink&gt;]. By March 2016, Breakthrough Therapy designation had been  granted by the FDA  [&lt;ulink linkID="1739909" linkType="Reference"&gt;1739909&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In May 2016, the EMA accepted the Accelerated Assessment  request for a planned MAA filing [&lt;ulink linkID="1758453" linkType="Reference"&gt;1758453&lt;/ulink&gt;]. By July 2016, the MAA had been submitted to the EMA [&lt;ulink linkID="1783619" linkType="Reference"&gt;1783619&lt;/ulink&gt;]. In September 2016, the MAA was validated by the EMA [&lt;ulink linkID="1796704" linkType="Reference"&gt;1796704&lt;/ulink&gt;], [&lt;ulink linkID="1903957" linkType="Reference"&gt;1903957&lt;/ulink&gt;]. In April 2017, EMA's CHMP granted a positive opinion for  approval in pediatric patients [&lt;ulink linkID="1919777" linkType="Reference"&gt;1919777&lt;/ulink&gt;]. In June 2017, cerliponase alfa was approved in the EU, Norway, Iceland and Liechtenstein, for the treatment of  pediatric patients from birth with CLN2 [&lt;ulink linkID="1933418" linkType="Reference"&gt;1933418&lt;/ulink&gt;], [&lt;ulink linkID="2125627" linkType="Reference"&gt;2125627&lt;/ulink&gt;]. In July 2017, the product was launched in France and Germany [&lt;ulink linkID="1950058" linkType="Reference"&gt;1950058&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2013, the COMP of the EMA recommended granting Orphan status for the treatment of CLN2   [&lt;ulink linkID="1383024" linkType="Reference"&gt;1383024&lt;/ulink&gt;]; in March 2013, Orphan status was granted [&lt;ulink linkID="1411042" linkType="Reference"&gt;1411042&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In September 2018, cerliponase alfa was awarded Orphan designation in Japan for treatment of ceroid lipofuscinosis type 2 [&lt;ulink linkID="2124739" linkType="Reference"&gt;2124739&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;In December 2018, cerliponase alfa was registered in Canada as Brineura [&lt;ulink linkID="2110105" linkType="Reference"&gt;2110105&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;In 2Q17, the drug was launched in Argentina [&lt;ulink linkID="1950058" linkType="Reference"&gt;1950058&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;In November 2017, the Australian TGA granted cerliponase alfa (Brineura) Orphan drug designation for treatment of CLN2 disease; the designation would lapse in May 2018 [&lt;ulink linkID="2010302" linkType="Reference"&gt;2010302&lt;/ulink&gt;]. Later in November 2017, the drug was granted priority review designation for the treatment of CLN2 disease; the  designation would lapse in May 2018 [&lt;ulink linkID="2010261" linkType="Reference"&gt;2010261&lt;/ulink&gt;]. In August 2018, cerliponase alfa (Brineura) was registered in Australia for treatment of CLN2 disease [&lt;ulink linkID="2071703" linkType="Reference"&gt;2071703&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In February 2015, a multicenter, multinational, single group assignment, open label, phase I/II extension study (&lt;ulink linkID="233616" linkType="Protocol"&gt;NCT02485899&lt;/ulink&gt;; 190-202)  was initiated in the US, Germany, Italy and the UK to evaluate the long-term efficacy and safety of cerliponase alfa in patients (n = 23) with CLN2  who had completed   the 190-201 study [&lt;ulink linkID="2068055" linkType="Reference"&gt;2068055&lt;/ulink&gt;]. In February 2017, interim results  were presented at the 13th Annual Lysosomal Disease Network WORLD Symposium in San Diego, CA. Patients completing the 190-201 study continued to receive intracerebroventricular infusion of cerliponase alfa (300 mg, qow) for up to 240 weeks. Adverse events were reported by all patients, and the common ones were grade 1 to 2 events. In cerliponase alfa treated patients, significant attenuation of the rate of decline in motor and language score was observed compared with untreated patients (0.32 versus 2.0 points/48 weeks, respectively). The responder (&amp;lt; 2 point loss) rate at week-81 (87%) was comparable to rate at week-48   [&lt;ulink linkID="1900573" linkType="Reference"&gt;1900573&lt;/ulink&gt;], [&lt;ulink linkID="1901605" linkType="Reference"&gt;1901605&lt;/ulink&gt;]. In September 2017, further data were presented at the 13th ICIEM in Rio de Janeiro, Brazil. Adverse events (AEs) were reported in all patients and were of grade 1 to 2 severity. The common AEs reported were pyrexia, hypersensitivity and convulsion [&lt;ulink linkID="1966171" linkType="Reference"&gt;1966171&lt;/ulink&gt;]. In December 2017, further data were presented at the 71st American Epilepsy Society Annual Meeting in Washington DC. At least one serious AE was reported by 20 patients, which was mostly consistent with neurodegenerative disease in a pediatric population. At week 96, there was an improvement in responder rate (100%, p &amp;lt; 0.0001) when compared to week 48 which suggested that the treatment had a persistent treatment effect [&lt;ulink linkID="1992594" linkType="Reference"&gt;1992594&lt;/ulink&gt;]. In February 2018, further year two results were presented at the 14th Annual Lysosomal Disease Network WORLD Symposium in San Diego, CA. When compared to rate of decline of 2.0 points/48 weeks in untreated patients, treated patients demonstrated a significant attenuation in the rate of decline in motor and language score to a median of 0.27 points/48 weeks. When compared to week 48, patients achieved 100% improvement in responder (&amp;lt; 2 point loss per 48 weeks) rate at week 96 (p &amp;lt; 0.0001), which suggested that effect of treatment was persistent [&lt;ulink linkID="2009562" linkType="Reference"&gt;2009562&lt;/ulink&gt;]. In April 2018, similar data were published [&lt;ulink linkID="2027227" linkType="Reference"&gt;2027227&lt;/ulink&gt;], [&lt;ulink linkID="2027555" linkType="Reference"&gt;2027555&lt;/ulink&gt;]. In May 2018, the study was expected to complete in January 2021 [&lt;ulink linkID="2068055" linkType="Reference"&gt;2068055&lt;/ulink&gt;]. In September 2018, further data were presented at the 2018 SSIEM Annual Symposium in Athens, Greece. At 96 weeks, the responder rate (87%, p &amp;lt; 0.0001) was stable compared to 48 weeks [&lt;ulink linkID="2068464" linkType="Reference"&gt;2068464&lt;/ulink&gt;]. Further data were reported in November 2018. All 23 enrolled patients showed continued maintenance of stabilization of disease for 3 years or more as measured by the CLN2 Clinical Rating Scale as compared to untreated patients from a natural history cohort [&lt;ulink linkID="2091640" linkType="Reference"&gt;2091640&lt;/ulink&gt;]. In February 2019, three-year  data were reported showing continued  durability of treatment effect with  a responder rate of 83%. At three years on treatment patients'  motor and language scores were an average of  3.8 points greater than the scores observed for the natural history cohort of CLN2 disease. At that time, 21 of 23 patients enrolled in the extension study were continuing in the extension; the discontinuation of two patients  was not due to adverse events [&lt;ulink linkID="2117668" linkType="Reference"&gt;2117668&lt;/ulink&gt;]. Later that month, further three year data were presented at the 15th Annual Lysosomal Disease Network WORLD Symposium in Orlando, FL. The rate of decline in Motor and Language domains scores (mean: 0.20 points/48 weeks, p &amp;lt; 0.0001) was significantly reduced in cerliponase alfa-treated subjects compared to the rate of decline in untreated patients (2 points/48 weeks) and improved since prior analysis at 48 weeks (0.4 points/48 weeks). Serious adverse events of hypersensitivity and device-related infections were reported in 83% subjects [&lt;ulink linkID="2118979" linkType="Reference"&gt;2118979&lt;/ulink&gt;]. &lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;In April 2013, BioMarin submitted a clinical trial application (CTA) with the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK [&lt;ulink linkID="1398130" linkType="Reference"&gt;1398130&lt;/ulink&gt;]. In September 2013, the single-group, open-label, dose-escalation, 48-week, phase I/II trial (&lt;ulink linkID="147413" linkType="Protocol"&gt;NCT01907087&lt;/ulink&gt;; 190-201) was initiated in the US, Germany, Italy and the UK to evaluate safety, tolerability, pharmacokinetics and efficacy of intracerebroventricular cerliponase alfa in patients ( n= 24) with CLN2 disease. The primary endpoints were to evaluate the safety of every other week infusions of cerliponase alfa based on measures such as vital signs, physical examination and ECG tests, and to  evaluate the efficacy of every other week infusions of cerliponase alfa by monitoring changes in clinical measures as measured by the NCL-2 disease rating scale [&lt;ulink linkID="1464860" linkType="Reference"&gt;1464860&lt;/ulink&gt;]. In January 2015, interim data were reported showing that cerliponase alfa appeared to stabilize the disease, with six of the nine patients showing no net change in CLN2 rating score and the other three showing a one point decline  [&lt;ulink linkID="1626072" linkType="Reference"&gt;1626072&lt;/ulink&gt;]. Also in January 2015, it was announced that the trial was fully enrolled with 24 patients [&lt;ulink linkID="1626437" linkType="Reference"&gt;1626437&lt;/ulink&gt;]. In November 2015, the study was complete [&lt;ulink linkID="1464860" linkType="Reference"&gt;1464860&lt;/ulink&gt;]. In March 2016, data were presented at the 12th Annual WORLDSymposium 2016. An 80% reduction in clinical disease progression in one year compared to natural history was observed (the primary efficacy endpoint). The drug was generally safe and well-tolerated in 24 patients and resulted in disease stabilization in 65%  of patients treated over a 48-week period. At that time, additional analysis were expected to be presented at the international Child Neurology Congress in Amsterdam, the Netherlands, in May, 2016 [&lt;ulink linkID="1739909" linkType="Reference"&gt;1739909&lt;/ulink&gt;].  In June 2016, further clinical data were presented at the 13th EILAT Conference on New Antieplieptic Drugs and Devices in Madrid, Spain. In 21 evaluable subjects, mean /median rate of decline in CLN2 score was 0.43/0.0 units; while in 41 natural history patients, rate of decline in CLN2 score was 2.09/1.87 units per 48 weeks. Overall, enzyme replacement therapy with intracerebroventricular-administered cerliponase alfa is well-tolerated and slowed the progression of functional decline. [&lt;ulink linkID="1779516" linkType="Reference"&gt;1779514&lt;/ulink&gt;]. In September 2016, additional data from the trial were reported.   Patients treated with cerliponase alfa continued to have motor-language (ML) scores after 81 weeks of treatment. The Hamburg Motor + Language CLN2 scoresÂ of a majority of treated patients were stable. The estimated rate of decline including approximately eight months of additional data continued to show substantial attenuation of disease progression with cerliponase alfa treatment. The Motor Language score   rate was improved from the corresponding rate of decline reported in the original BLA of 0.48 (0.16, 0.81), which was based on 48 weeks of treatment  [&lt;ulink linkID="1794460" linkType="Reference"&gt;1794460&lt;/ulink&gt;]. In September 2016, results from the trial presented at the 2016 Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Meeting in Rome, Italy. A total of 96% subjects reported adverse events (AEs) which were assessed as study drug-related. Majority of the AEs were grade 1 to 2 and included pyrexia, hypersensitivity, seizure and epilepsy reported by 46, 38, 38 and 17% of patients, respectively. A total of 33% of patients reported serious AEs which were assessed by the investigator as study drug-related [&lt;ulink linkID="1894733" linkType="Reference"&gt;1894733&lt;/ulink&gt;]. In February 2017, results were presented at the 13th Annual WORLD Symposium San Diego, CA. In patients (n = 24) treated with cerliponase alfa, anti-drug antibody (ADA) production was induced in the serum and cerebrospinal fluid of 79 and 21% of patients, respectively. Despite a significantly higher drug exposure in the CSF, the extent of the ADA response was different between these two compartments, with the peak response being approximately 100 times lesser in magnitude in the CSF when compared with that observed in the serum   [&lt;ulink linkID="1900573" linkType="Reference"&gt;1900573&lt;/ulink&gt;], [&lt;ulink linkID="1901623" linkType="Reference"&gt;1901623&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In May 2018, in vivo data were presented at 2018 ARVO Meeting in Honolulu, HI. In ERG responses and retinal anatomical parameters IVT human tripeptidyl peptidase 1 attenuated or prevented the progressive disease was relative to the vehicle. In TPP1-null dogs, ERT with repeated IVT administration prior to disease onset inhibited the progression of disease related retinal degeneration [&lt;ulink linkID="2028763" linkType="Reference"&gt;2028763&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2018, in vivo data were presented at the 14th Annual Lysosomal Disease Network WORLD Symposium in San Diego, CA. Repeated intravitreal human TPP1 administration to TPP1-null dogs prior to disease onset inhibited the progression of disease-related retinal degeneration. In a dog treated after a significant decline in retinal function, further decline in electroretinogram  responses were prevented [&lt;ulink linkID="2009533" linkType="Reference"&gt;2009533&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In February 2013, preclinical data in naturally-occurring Batten disease in dachshund dogs were reported. Untreated dogs died from Batten disease at around 10 to 11 months of age whereas those that received cerliponase alfa administered directly to the spinal fluid once every 2 weeks had significantly delayed onset of symptoms and lived substantially longer [&lt;ulink linkID="1382986" linkType="Reference"&gt;1382986&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2012, data were presented at the 62nd Annual Meeting of the American Society of Human Genetics in San Francisco, CA. In canine models with cLINCL, recombinant human tripeptidyl peptidase-1 (rhTPP1) was associated with elevated CSF TTP1 levels for 48 h after administration, which was 1000-fold higher than plasma levels. Treatment with rhTPP1 restored pupillary light reflexes near to wild-type levels. An increase in the mean survival from 43 weeks (in vehicle treated controls) to 54 and 62 weeks was observed in 4 and 16 mg rhTPP1 groups, respectively [&lt;ulink linkID="1384511" linkType="Reference"&gt;1384511&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2011, preclinical data in animal models of LINCL had demonstrated pharmacological effects, including functional improvement and life extension. Pharmacokinetic profile and CNS distribution were favorable after  intracerebroventricular infusion [&lt;ulink linkID="1247049" linkType="Reference"&gt;1247049&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In November and December 2017, the FDA and the EMA, respectively, approved the company's Shanbally facility as a formulated bulk drug substance manufacturing and quality control facility for cerliponase [&lt;ulink linkID="2008438" linkType="Reference"&gt;2008438&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2013, the EMA's Pediatric Committee (PDCO) adopted a positive opinion agreeing a pediatric investigation plan (PIP) for enzyme replacement therapy for the treatment of NCL-2   [&lt;ulink linkID="1481266" linkType="Reference"&gt;1481266&lt;/ulink&gt;]. In September 2016, the PDCO completed a compliance check on the granted PIP [&lt;ulink linkID="1886549" linkType="Reference"&gt;1886549&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2057">Jansky-Bielschowsky disease</Indication><StatusDate>2017-07-31T00:00:00.000Z</StatusDate><Source id="1950058" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2057">Jansky-Bielschowsky disease</Indication><StatusDate>2017-07-31T00:00:00.000Z</StatusDate><Source id="1950058" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2057">Jansky-Bielschowsky disease</Indication><StatusDate>2017-06-30T00:00:00.000Z</StatusDate><Source id="1950058" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2057">Jansky-Bielschowsky disease</Indication><StatusDate>2017-06-30T00:00:00.000Z</StatusDate><Source id="1950058" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2057">Jansky-Bielschowsky disease</Indication><StatusDate>2017-06-01T00:00:00.000Z</StatusDate><Source id="2125627" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="NO">Norway</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2057">Jansky-Bielschowsky disease</Indication><StatusDate>2017-06-01T00:00:00.000Z</StatusDate><Source id="2125627" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2057">Jansky-Bielschowsky disease</Indication><StatusDate>2017-06-01T00:00:00.000Z</StatusDate><Source id="1933418" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2057">Jansky-Bielschowsky disease</Indication><StatusDate>2018-08-28T00:00:00.000Z</StatusDate><Source id="2071703" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="LI">Liechtenstein</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2057">Jansky-Bielschowsky disease</Indication><StatusDate>2017-06-01T00:00:00.000Z</StatusDate><Source id="2125627" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2057">Jansky-Bielschowsky disease</Indication><StatusDate>2018-12-19T00:00:00.000Z</StatusDate><Source id="2110105" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2057">Jansky-Bielschowsky disease</Indication><StatusDate>2018-09-14T00:00:00.000Z</StatusDate><Source id="2124739" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20638">University of Medicine and Dentistry of New Jersey</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2057">Jansky-Bielschowsky disease</Indication><StatusDate>2011-12-08T00:00:00.000Z</StatusDate><Source id="1247049" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2057">Jansky-Bielschowsky disease</Indication><StatusDate>2013-09-12T00:00:00.000Z</StatusDate><Source id="1464860" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2057">Jansky-Bielschowsky disease</Indication><StatusDate>2013-09-12T00:00:00.000Z</StatusDate><Source id="1464860" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2057">Jansky-Bielschowsky disease</Indication><StatusDate>2011-12-08T00:00:00.000Z</StatusDate><Source id="1247049" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2057">Jansky-Bielschowsky disease</Indication><StatusDate>2016-07-27T00:00:00.000Z</StatusDate><Source id="1783619" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2057">Jansky-Bielschowsky disease</Indication><StatusDate>2016-07-27T00:00:00.000Z</StatusDate><Source id="1783619" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2057">Jansky-Bielschowsky disease</Indication><StatusDate>2017-04-27T00:00:00.000Z</StatusDate><Source id="1922126" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25861">BioMarin Pharmaceutical Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2057">Jansky-Bielschowsky disease</Indication><StatusDate>2017-11-30T00:00:00.000Z</StatusDate><Source id="2010261" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="25861">BioMarin Pharmaceutical Inc</OwnerCompany><Country id="JP">Japan</Country><Indication id="2057">Jansky-Bielschowsky disease</Indication><AwardedIndication>Treatment of ceroid lipofuscinosis type 2</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-09-14T00:00:00.000Z</MileStoneDate><Source id="2124739" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="25861">BioMarin Pharmaceutical Inc</OwnerCompany><Country id="AU">Australia</Country><Indication id="2057">Jansky-Bielschowsky disease</Indication><AwardedIndication>Treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-11-08T00:00:00.000Z</MileStoneDate><Source id="2010302" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="25861">BioMarin Pharmaceutical Inc</OwnerCompany><Country id="US">US</Country><Indication id="2057">Jansky-Bielschowsky disease</Indication><AwardedIndication>Treatment of neuronal ceroid lipofuscinosis type 2</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2013-04-01T00:00:00.000Z</MileStoneDate><Source id="1398195" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="25861">BioMarin Pharmaceutical Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="2057">Jansky-Bielschowsky disease</Indication><AwardedIndication>Treatment of neuronal ceroid lipofuscinosis type 2</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2013-03-12T00:00:00.000Z</MileStoneDate><Source id="1411042" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="25861">BioMarin Pharmaceutical Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="2057">Jansky-Bielschowsky disease</Indication><AwardedIndication>Treatment of neuronal ceroid lipofuscinosis type 2</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2013-02-06T00:00:00.000Z</MileStoneDate><Source id="1383024" type="PR"/></Row><Row><RegulatoryDesignation id="9">Paediatric Investigation Plan</RegulatoryDesignation><OwnerCompany id="25861">BioMarin Pharmaceutical Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="2057">Jansky-Bielschowsky disease</Indication><AwardedIndication>Treatment of neuronal ceroid lipofuscinosis type 2</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2013-09-20T00:00:00.000Z</MileStoneDate><Source id="1481266" type="PR"/></Row><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="25861">BioMarin Pharmaceutical Inc</OwnerCompany><Country id="AU">Australia</Country><Indication id="2057">Jansky-Bielschowsky disease</Indication><AwardedIndication>Treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-11-30T00:00:00.000Z</MileStoneDate><Source id="2010261" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="13">Rare Pediatric Disease</RegulatoryDesignation><OwnerCompany id="25861">BioMarin Pharmaceutical Inc</OwnerCompany><Country id="US">US</Country><Indication id="2057">Jansky-Bielschowsky disease</Indication><AwardedIndication>Treatment of CLN2 disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-04-27T00:00:00.000Z</MileStoneDate><Source id="1922126" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-06306"><Name>Tripeptidyl peptidase 1</Name><SwissprotNumbers><Swissprot>O14773</Swissprot><Swissprot>O89023</Swissprot><Swissprot>Q0V8B6</Swissprot><Swissprot>Q5IS74</Swissprot><Swissprot>Q5RFL1</Swissprot><Swissprot>Q60HH1</Swissprot><Swissprot>Q9EQV6</Swissprot><Swissprot>Q9XSB8</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2145336" linkType="reference" linkID="2145336"&gt;2145336&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="21239">Rutgers University</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="25861">BioMarin Pharmaceutical Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="10">Technology - Other Proprietary</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="150383" title="BioMarin Pharmaceutical to develop UMDNJ's BMN-190 for the treatment of LINCL "/><Deal id="244255" title="BioMarin Pharmaceutical to sell Rare Pediatric Disease Priority Review Voucher to undisclosed company"/></Deals><PatentFamilies><PatentFamily id="28829" number="WO-00185200" title="Recombinant human CLN2 protein and methods of its production and use"/><PatentFamily id="3441549" number="WO-2016182862" title="Tpp1 formulations and methods for treating cln2 disease"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Rutgers University" id="21239"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BioMarin Pharmaceutical Inc" id="25861"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></drugRecordOutput>